{
  "docId": "019de074-704c-735b-b7a3-613838aa1bf3",
  "docSlug": "9b81d8a09c69afc3f139dc970effabde",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 39,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Includes a biological process diagram showing intracellular vs plasma metabolism.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/11",
  "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3",
  "deckJsonHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3.json",
  "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.52,
        "x": 0.05,
        "y": 0.285
      },
      "kind": "image",
      "text": "Depiction of Normal and Therapeutic Metabolism",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "823c85c4-2c0d-4c29-8c0f-a63d99b40060",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.6,
        "y": 0.62
      },
      "kind": "list",
      "text": "Elevated levels of plasma total homocysteine increase risk for disease manifestations. Reduction of plasma total homocysteine has been correlated with reduced risk. Generally accepted aim of treatment is to lower concentration.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5379e585-b831-4184-b8ee-542a63e07cf0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.6,
        "y": 0.35
      },
      "kind": "list",
      "text": "Concentration gradient drives homocysteine out of tissues and into plasma. Equilibrium in plasma favors dimer over monomer. Flux enables further metabolism of both monomer and dimer.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8de855b7-ce2c-43d0-9020-4c60aebb1f70",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.55,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1Mudd, Skovby et al. 1985, Al-Dewik, Ali et al. 2019; 2Mudd, Skovby et al. 1985, Wilcken and Wilcken 1997, Yap and Naughten 1998",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b9fc7fd-c302-4f0c-927c-95faa4a6ea43",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "Pegtarviliase: An Innovative Enzyme Approach to Lowering Homocysteine",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a39c7d3-344c-4131-acb9-9439412e0f9e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Analytical method",
      "slug": "analytical-method",
      "agent": null,
      "layer": "slide",
      "matchId": "e9db35d7-114b-4a84-8e60-b508e4256d27",
      "evidence": "The slide explains the mechanism of action of Pegtarviliase and how it works to lower homocysteine levels.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 11,
      "beatId": "e2814c7d-564b-4c74-ad47-085d9e1b3afc",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Aeglea BioTherapeutics' therapies as a solution to the problems associated with classical homocystinuria and arginase 1 deficiency.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 10,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "7b5956cf-b800-4aec-9392-9fb9fb1da892",
      "evidence": "The document presents a market sizing analysis for classical homocystinuria.",
      "position": 2,
      "objective": "What is the market opportunity for Aeglea BioTherapeutics' therapies?",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.6,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}